TCIM and cancer: While, e.g., DCAF7 and CDH2 displayed continuous changes across lineage types occurring during cancer progression, others such as TCIM or BRIP1 were expressed transiently at higher levels in asymmetric or only in symmetric (i.e., only invasive tumor cell) lineages, respectively (Fig. 6e and Fig. S22e).